3,408,291 Shares in Edwards Lifesciences Corporation $EW Acquired by Primecap Management Co. CA

Primecap Management Co. CA purchased a new position in Edwards Lifesciences Corporation (NYSE:EW) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 3,408,291 shares of the medical research company’s stock, valued at approximately $308,314,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. BlackRock Inc. acquired a new position in shares of Edwards Lifesciences in the 2nd quarter valued at approximately $5,318,092,000. State Street Corp boosted its position in shares of Edwards Lifesciences by 1.5% during the 4th quarter. State Street Corp now owns 25,991,524 shares of the medical research company’s stock worth $2,215,777,000 after acquiring an additional 371,892 shares in the last quarter. Wellington Management Group LLP increased its stake in Edwards Lifesciences by 4.8% in the fourth quarter. Wellington Management Group LLP now owns 21,793,949 shares of the medical research company’s stock valued at $1,857,934,000 after acquiring an additional 989,533 shares during the last quarter. Bank of New York Mellon Corp bought a new position in Edwards Lifesciences in the second quarter valued at approximately $1,274,082,000. Finally, Norges Bank acquired a new position in Edwards Lifesciences during the fourth quarter valued at approximately $803,686,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Stock Up 0.5%

Edwards Lifesciences stock opened at $90.92 on Wednesday. The firm has a market cap of $52.35 billion, a price-to-earnings ratio of 52.25, a PEG ratio of 2.37 and a beta of 0.85. Edwards Lifesciences Corporation has a 52-week low of $72.30 and a 52-week high of $96.29. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.77 and a current ratio of 4.52. The firm has a 50 day moving average price of $89.35 and a two-hundred day moving average price of $84.82.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The firm had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.70 billion. During the same period last year, the company posted $0.67 EPS. The business’s quarterly revenue was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Equities analysts predict that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Insiders Place Their Bets

In related news, VP Daniel J. Lippis sold 619 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total transaction of $56,966.57. Following the completion of the sale, the vice president owned 40,034 shares in the company, valued at approximately $3,684,329.02. This trade represents a 1.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 568 shares of the business’s stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $86.08, for a total value of $48,893.44. Following the completion of the sale, the senior vice president owned 15,334 shares in the company, valued at $1,319,950.72. This represents a 3.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 2,425 shares of company stock valued at $219,199 in the last 90 days. 0.31% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. Evercore reaffirmed an “outperform” rating and issued a $100.00 price objective on shares of Edwards Lifesciences in a research note on Monday, July 6th. UBS Group assumed coverage on Edwards Lifesciences in a research note on Tuesday, July 28th. They set a “buy” rating and a $110.00 target price for the company. Mizuho increased their target price on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “outperform” rating in a report on Wednesday, July 15th. Truist Financial raised their price target on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the company a “hold” rating in a research note on Thursday, July 16th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the company an “overweight” rating in a report on Friday, July 24th. Seventeen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, Edwards Lifesciences has an average rating of “Moderate Buy” and an average target price of $100.27.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.